These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Merck & Co. Inc. CANCIDAS® (caspofungin acetate) NCT00082524 Invasive Aspergillosis Esophageal Candidiasis invasive candidiasis Phase II http://www.merck.com/product/usa/pi_circulars/ Clinical Study Summary A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections. Publication planned. Merck Protocol Number: 043 http://clinicaltrials.gov/show/NCT00082524 The contents of this web site should not be interpreted as medical advice, and should not be relied upon as the basis for any decision or action. You should consult your health care professional for advice on your specific situation. Merck & Co., Inc. (Merck) will make good faith efforts to include accurate and current information on the ClinicalStudyResults.org web site, but because the status of studies often changes Merck makes no warranties or representations of any kind as to the currency or completeness of the information contained therein, and disclaims all warranties, express or implied, with respect to such information. Merck shall not be liable for any damages, including, without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to access or use information posted by Merck on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. Company Study CANCIDAS®_043 Back to Search Results